Optinose, INC

Paratek Pharmaceuticals has completed its acquisition of Optinose, broadening its commercial portfolio with the addition of XHANCE to its existing antibiotic, NUZYRA.

OptiNose, Inc. stockholders voted to approve the merger agreement with Paratek Pharmaceuticals at a special meeting held on May 16, 2025.

Optinose reports a 13% increase in Q4 XHANCE net revenue and a 23% prescription growth from Q3 to Q4 2024.

OptiNose enters into a definitive agreement to be acquired by Paratek Pharmaceuticals for $9.00 per share in cash plus a contingent value right.

Paratek Pharmaceuticals will acquire Optinose for up to $330 million, aiming to leverage Paratek's commercial infrastructure to expand the reach of XHANCE, a treatment for chronic rhinosinusitis, to primary care providers.

Optinose reported preliminary unaudited net revenue of $22.4 million for XHANCE in the fourth quarter of 2024, with an estimated 20% sequential prescription growth rate.

OptiNose, Inc. announces its first quarter 2025 financial results, showcasing increased XHANCE prescriptions and revenue per prescription, while also addressing liquidity concerns and an impending merger with Paratek Pharmaceuticals.

OptiNose's Q3 2024 results show a slight revenue increase, driven by changes to their co-pay program, despite a decrease in overall prescriptions.

OptiNose's Q2 2024 revenue increased due to higher net revenue per prescription, despite a decrease in overall prescription volume.

OptiNose, Inc. reported a 25% increase in net product revenue for the first quarter of 2024, driven by higher average revenue per prescription, despite a decrease in overall prescription volume.

Optinose files an amendment to its 2024 Annual Report on Form 10-K/A to include Part III information and update certain disclosures, coinciding with a pending merger agreement with Paratek Pharmaceuticals.

OptiNose, Inc. reports its annual results, highlighting XHANCE commercialization efforts and a pending merger with Paratek Pharmaceuticals, while acknowledging substantial doubt about its ability to continue as a going concern.

OptiNose's future is uncertain as it grapples with debt covenants and the need for additional capital, despite positive clinical trial results for its drug XHANCE.

Following the merger of OptiNose with Paratek Pharmaceuticals, Chief Legal Officer Michael F. Marino III reports the disposal of common stock and stock options.

Following the merger of OptiNose with Paratek Pharmaceuticals, CFO Terry Kohler reports the disposal of common stock and stock options as part of the merger agreement.

Director John Fletcher's stock options in OptiNose were canceled or converted to contingent value rights (CVRs) following the merger with Paratek Pharmaceuticals on May 21, 2025.

Sandra L. Helton, a director of OptiNose, Inc., reports changes in beneficial ownership of securities following the merger with Paratek Pharmaceuticals, including the conversion of stock options into cash and contingent value rights.

Following the merger of OptiNose with Paratek Pharmaceuticals, a director's stock options were converted into cash and contingent value rights (CVRs) based on the merger agreement.

Paul Spence Jr., Chief Commercial Officer of OptiNose, Inc., reports the disposal of common stock and stock options due to the merger with Paratek Pharmaceuticals, Inc.

OptiNose provides supplemental disclosures to its definitive proxy statement related to its merger with Paratek Pharmaceuticals in response to stockholder litigation alleging misrepresentations.

OptiNose addresses employee concerns regarding pay, benefits, and job security following the pending merger with Paratek Pharmaceuticals.

OptiNose and Paratek provide an update on integration planning following their executive leadership meeting, anticipating the merger to close around May 21, 2025, pending shareholder approval and regulatory clearances.

OptiNose, Inc. has scheduled a special meeting on May 16, 2025, for shareholders to vote on the proposed merger with Paratek Pharmaceuticals, Inc.

OptiNose, Inc. has scheduled a special meeting for stockholders to vote on the proposed merger agreement with Paratek Pharmaceuticals, Inc., where stockholders will receive $9.00 per share in cash and a contingent value right (CVR) representing the right to receive up to $5.00 in contingent cash payments.

OptiNose and Paratek Pharmaceuticals have entered into a merger agreement where Paratek will acquire OptiNose for a potential value of $330 million, pending shareholder approval and customary closing conditions.

Option Therapeutics Inc., a BioVie subsidiary, is launching its initial public offering to fund the Phase 3 clinical trial of BIV201, an investigational drug for advanced liver cirrhosis complications, aiming to raise $17.0 million.

Nantahala Capital Management and its principals have reported zero beneficial ownership in Optinose, Inc. as of June 30, 2025, indicating a full divestment.

Rosalind Advisors, Inc. and related entities have reported a complete divestment of their beneficial ownership in OptiNose, Inc., now holding 0% of common shares.